Special Education and Applied Behavior Analysis in Turkey

Applied Behavior Analysis

Subscribe to Applied Behavior Analysis: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Applied Behavior Analysis: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

Related Topics: Applied Behavior Analysis, Disability Nexus

News Feed Item

Tuberous Sclerosis Alliance to Present 14th Annual Comedy for a Cure®

SILVER SPRING, Md., April 3, 2015 /PRNewswire-USNewswire/ -- On Sunday, April 12, the Tuberous Sclerosis Alliance (TS Alliance) will present its 14th Annual Comedy for a Cure® at The Globe Theater in Universal City, CA.  The event raises funds to further research on tuberous sclerosis complex (TSC) and to underwrite support programs for people with TSC.  Comedy for a Cure has been a key cause within the entertainment industry and comedy community, raising almost $4 million over the last 13 years.

TS Alliance Logo.

The night begins at 5:30 pm with red carpet arrivals. Next are a one-hour cocktail reception and silent auction, followed by a live auction and ending with comedy performances by Mark Eddie and Craig ShoemakerMo Collins will serve as emcee and will be joined by the event's Honorary Chair, Jim O'Heir.

In addition, Comedy for a Cure will recognize the Ron Heffron Family with the Courage in Leadership Award. "The Heffrons have been instrumental in guiding the TS Alliance's efforts to expand services and influence research through raising awareness of the organization, serving on national research review panels and being on the TS Alliance's Board of Directors," said Kari Luther Rosbeck, TS Alliance President & CEO. "Through their time, expertise and compassionate commitment, Ron and Ann have had a tremendous impact on quality of life for all individuals affected by TSC."  

The TS Alliance will also honor Helena Foulkes, President, CVS/pharmacy and Executive Vice President, CVS Health. CVS Health first got involved in Comedy for a Cure in 2005 and has continued to support the event through generous sponsorships. "Helena has served on the honorary committee of Comedy for a Cure since 2012 and has been instrumental in TS Alliance government advocacy efforts by garnering Congressional support for the appropriation for TSC research in the Congressionally Directed Medical Research Program budget," Rosbeck explained.

Moreover, since FDA approval of Sabril® (vigabatrin) in 2009, CVS Health has served as one of four specialty pharmacies that distribute the medication based on very strict safety requirements. "Under Helena's leadership, CVS Health has gone above and beyond to ensure the needs of children and adults with TSC are met through timely medication delivery and by working tirelessly with the TSC community and insurance companies to mediate any issues with coverage," Rosbeck continued.

TSC is a multi-system genetic disorder that causes tumors to form in vital organs, primarily the brain, heart, eyes, kidneys, lungs and skin. It's also the leading genetic cause of both autism and epilepsy.  Approximately 50,000 people in the United States suffer from the disease, and it has an estimated incidence of 1 in 6,000 live births.  More than 1 million people worldwide have TSC.

Formed in 1974, the TS Alliance is the only U.S.-based non-profit organization dedicated to finding a cure for TSC while improving the lives of those affected.  For more information about Comedy for a Cure, visit www.ComedyforaCure.org. For inquiries about TSC or the TS Alliance, visit www.tsalliance.org

For more information contact:
Jaye D. Isham, Vice President, Communications Strategy
(301) 562-9890, [email protected]

Logo - http://photos.prnewswire.com/prnh/20150313/181579LOGO


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tuberous-sclerosis-alliance-to-present-14th-annual-comedy-for-a-cure-300055232.html

SOURCE Tuberous Sclerosis Alliance

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.